SummitTX Capital L.P. lifted its holdings in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) by 86.4% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 327,997 shares of the company’s stock after buying an additional 152,049 shares during the period. SummitTX Capital L.P.’s holdings in Eupraxia Pharmaceuticals were worth $2,375,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Affinity Asset Advisors LLC boosted its stake in Eupraxia Pharmaceuticals by 429.7% in the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after buying an additional 1,289,005 shares in the last quarter. Vivo Capital LLC bought a new position in Eupraxia Pharmaceuticals in the third quarter valued at about $7,965,000. Ikarian Capital LLC acquired a new position in Eupraxia Pharmaceuticals during the fourth quarter worth about $4,606,000. Squadron Capital Management LLC acquired a new position in Eupraxia Pharmaceuticals during the fourth quarter worth about $3,775,000. Finally, Velan Capital Investment Management LP bought a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth about $2,077,000.
Eupraxia Pharmaceuticals Price Performance
Eupraxia Pharmaceuticals stock opened at $6.10 on Wednesday. The stock has a 50-day moving average price of $6.50 and a two-hundred day moving average price of $7.33. Eupraxia Pharmaceuticals Inc. has a 12 month low of $5.04 and a 12 month high of $9.32. The company has a market capitalization of $396.62 million, a PE ratio of -5.81 and a beta of 1.05. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02.
Analysts Set New Price Targets
A number of research firms have recently weighed in on EPRX. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Stifel Nicolaus started coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a “buy” rating and a $25.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eupraxia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.
Check Out Our Latest Analysis on Eupraxia Pharmaceuticals
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.
Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding EPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report).
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
